NASDAQ:GRI GRI Bio (GRI) Stock Price, News & Analysis 0.38 0.00 (-1.00%) (As of 12/29/2023 09:01 PM ET) Add Compare Share Share Today's Range0.35▼0.4050-Day Range0.33▼1.2752-Week Range0.32▼36.90Volume284,700 shsAverage Volume671,557 shsMarket Capitalization$1.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media About GRI Bio Stock (NASDAQ:GRI)GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention-deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in Philadelphia, Pennsylvania.Read More GRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRI Stock News HeadlinesDecember 29, 2023 | americanbankingnews.comGRI Bio, Inc. (NASDAQ:GRI) Short Interest Up 194.2% in DecemberDecember 21, 2023 | msn.comGRI Bio files to sell common stock, warrantsDecember 31, 2023 | MarketBeat Internal (Ad)New Year's Sale: Get MarketBeat All Access Free For 30 DaysAccess our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscriptionNovember 27, 2023 | markets.businessinsider.comGRI Bio Says FDA Clears IND For GRI-0621 For Treatment Of IPF; Stock Up 19%November 27, 2023 | msn.comGRI Bio stock slides 9% amid FDA clearance for testing of IPF drugNovember 24, 2023 | morningstar.comGRI Bio Inc GRINovember 15, 2023 | finanznachrichten.deGRI Bio, Inc.: GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 15, 2023 | msn.comGRI Bio reports Q3 resultsDecember 31, 2023 | MarketBeat Internal (Ad)Claim Your $300 MarketBeat Account CreditClick the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)November 6, 2023 | msn.comLawsuit alleges plan to open a marijuana store in former Rainforest Cafe is illegalOctober 31, 2023 | chicago.suntimes.comPot shop company files suit to blunt planned dispensary at former Rainforest Cafe, limit proximity of minority-owned storesOctober 17, 2023 | markets.businessinsider.comGRI Bio Partners With NIHR Respiratory TRC To Advance NKT Regulation Technology - Quick FactsOctober 11, 2023 | finance.yahoo.comGRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO ConferenceSeptember 29, 2023 | finanznachrichten.deGRI Bio, Inc.: September Is Pulmonary Fibrosis Awareness Month: Here's What One Company Is Doing To Develop A Treatment For This Deadly DiseaseSeptember 18, 2023 | benzinga.comThinking about buying stock in SeqLL, GRI Bio, Earlyworks Co, TradeUP Acquisition, or Safety Shot?September 15, 2023 | benzinga.comDisease With Market Estimated At $3.9 Billion Lacks Cure – Will This Company Be The First To Find One?September 8, 2023 | msn.comElon Musk blocked Ukrainian attack on Russia's Black Sea fleet, says new biographySeptember 1, 2023 | finance.yahoo.comIPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?August 29, 2023 | finance.yahoo.comGRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement CampaignAugust 25, 2023 | finance.yahoo.comGRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And LupusAugust 24, 2023 | benzinga.comThinking about buying stock in MicroCloud Hologram, AgileThought, GRI Bio, Profire Energy, or Foot Locker?August 23, 2023 | marketwatch.comGRI Bio Shares Slide to 52-Week Low Amid Sale of Adair Asset >GRIAugust 23, 2023 | finance.yahoo.comGRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIRAugust 14, 2023 | finance.yahoo.comGRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 8, 2023 | benzinga.comGRI Bio Head Talks Macro Picture For Biotech At Benzinga WebinarAugust 8, 2023 | finance.yahoo.comGRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal ModelsAugust 3, 2023 | finance.yahoo.comGRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech ConferenceSee More Headlines Receive GRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRI Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRI CUSIPN/A CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)-11.64 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,020,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-595.60% Return on Assets-315.73% Debt Debt-to-Equity RatioN/A Current Ratio2.01 Quick Ratio2.01 Sales & Book Value Annual Sales$100,000.00 Price / Sales17.40 Cash FlowN/A Price / Cash FlowN/A Book Value5.52 per share Price / Book0.07Miscellaneous Outstanding Shares4,520,000Free Float3,376,000Market Cap$1.74 million OptionableNot Optionable Beta-1.53 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. W. Marc Hertz Ph.D. (Age 53)Co-Founder, CEO, President & Director Dr. Vipin Kumar Chaturvedi Ph.D. (Age 64)Co-Founder & Chief Scientific Officer Ms. Leanne M. Kelly (Age 46)CFO & Corporate Secretary Dr. Albert Agro Ph.d. (Age 58)Chief Medical Officer Key Competitors9 Meters BiopharmaNASDAQ:NMTRZyVersa TherapeuticsNASDAQ:ZVSAEvofem BiosciencesNASDAQ:EVFMScinai ImmunotherapeuticsNASDAQ:SCNI180 Life SciencesNASDAQ:ATNFView All Competitors GRI Stock Analysis - Frequently Asked Questions How have GRI shares performed in 2023? GRI Bio's stock was trading at 7.36 at the beginning of the year. Since then, GRI stock has decreased by 94.8% and is now trading at 0.39. View the best growth stocks for 2023 here. When is GRI Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 23rd 2024. View our GRI earnings forecast. How were GRI Bio's earnings last quarter? GRI Bio, Inc. (NASDAQ:GRI) announced its earnings results on Tuesday, November, 14th. The company reported ($0.52) earnings per share for the quarter. When did GRI Bio's stock split? Shares of GRI Bio reverse split on the morning of Monday, April 24th 2023. The 1-30 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of GRI Bio? Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRI) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.